Telemetry Investments, L.L.C. - STEMLINE THERAPEUTICS INC ownership

STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 100 filers reported holding STEMLINE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 5.69 and the average weighting 0.3%.

Quarter-by-quarter ownership
Telemetry Investments, L.L.C. ownership history of STEMLINE THERAPEUTICS INC
ValueSharesWeighting
Q1 2020$112,000
-70.1%
23,058
-34.6%
0.39%
-68.7%
Q4 2019$375,000
-9.9%
35,258
-11.9%
1.25%
+4.2%
Q3 2019$416,000
-20.2%
40,000
+17.6%
1.20%
+198.5%
Q2 2019$521,000
-18.8%
34,000
-32.0%
0.40%
+23.3%
Q1 2019$642,000
+62.5%
50,000
+20.2%
0.33%
+29.4%
Q4 2018$395,000
+104.7%
41,588
+245.1%
0.25%
+240.5%
Q2 2018$193,000
-31.8%
12,050
-34.9%
0.07%
-30.2%
Q1 2018$283,000
-27.4%
18,500
-26.0%
0.11%
-28.9%
Q4 2017$390,000
+90.2%
25,000
+35.1%
0.15%
+104.1%
Q3 2017$205,000
-10.9%
18,500
-26.0%
0.07%
-32.4%
Q2 2017$230,000
+14.4%
25,000
+6.2%
0.11%
+20.0%
Q1 2017$201,000
-25.0%
23,530
-5.9%
0.09%
-40.4%
Q4 2016$268,000
+7.6%
25,016
+8.8%
0.15%
-3.2%
Q3 2016$249,000
-12.6%
23,000
-45.4%
0.16%
+2.0%
Q2 2016$285,0000.0%42,121
-31.2%
0.15%
+84.3%
Q1 2016$285,000
-43.6%
61,244
-23.4%
0.08%
-51.7%
Q4 2015$505,000
-25.7%
80,000
+3.9%
0.17%
-40.9%
Q3 2015$680,000
-26.9%
77,000
-2.5%
0.29%
-30.7%
Q2 2015$930,000
+16.8%
79,000
+43.6%
0.42%
-4.3%
Q1 2015$796,000
+26.1%
55,000
+48.6%
0.44%
+12.3%
Q4 2014$631,00037,0000.39%
Other shareholders
STEMLINE THERAPEUTICS INC shareholders Q1 2019
NameSharesValueWeighting ↓
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 453,000$4,168,0001.58%
Eventide Asset Management 1,086,400$9,995,0000.62%
SPHERA FUNDS MANAGEMENT LTD. 300,000$2,760,0000.47%
Lyon Street Capital, LLC 125,595$1,155,0000.46%
CARL DOMINO INC 26,000$239,0000.28%
PURA VIDA INVESTMENTS, LLC 60,000$552,0000.22%
KNOTT DAVID M 41,692$384,0000.16%
SABBY MANAGEMENT, LLC 187,500$1,725,0000.11%
FARALLON CAPITAL MANAGEMENT LLC 1,157,500$10,649,0000.11%
Telemetry Investments, L.L.C. 25,000$230,0000.11%
View complete list of STEMLINE THERAPEUTICS INC shareholders